Aliases & Classifications for Vitreous Detachment

MalaCards integrated aliases for Vitreous Detachment:

Name: Vitreous Detachment 12 44 15 17 72
Posterior Vitreous Detachment 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9726
MeSH 44 D020255
NCIt 50 C50807
SNOMED-CT 68 53772007
ICD10 33 H43.81
UMLS 72 C0042907 C0423361

Summaries for Vitreous Detachment

MalaCards based summary : Vitreous Detachment, also known as posterior vitreous detachment, is related to macular retinal edema and macular holes, and has symptoms including eye manifestations An important gene associated with Vitreous Detachment is KCNMA1 (Potassium Calcium-Activated Channel Subfamily M Alpha 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Bevacizumab and Temazepam have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and cortex, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 75 A posterior vitreous detachment (PVD) is a condition of the eye in which the vitreous membrane separates... more...

Related Diseases for Vitreous Detachment

Diseases related to Vitreous Detachment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 30.6 VEGFA KCNMA1
2 macular holes 30.1 VEGFA LHFPL5 KCNMA1
3 endophthalmitis 29.8 VEGFA PLG
4 retinal vascular disease 29.6 VEGFA PLG
5 macular degeneration, age-related, 1 29.4 VEGFA PLG OPTC KCNMA1
6 retinal detachment 10.8
7 myopia 10.5
8 microvascular complications of diabetes 5 10.5
9 hydrops, lactic acidosis, and sideroblastic anemia 10.5
10 cataract 10.4
11 refractive error 10.4
12 diabetic macular edema 10.4
13 microvascular complications of diabetes 1 10.3
14 microvascular complications of diabetes 2 10.3
15 retinal vein occlusion 10.3
16 intraocular pressure quantitative trait locus 10.2
17 neuroretinitis 10.2
18 retinitis 10.2
19 retinal disease 10.2
20 exudative vitreoretinopathy 1 10.1
21 retinitis pigmentosa 10.1
22 open-angle glaucoma 10.1
23 peripheral retinal degeneration 10.1
24 uveitis 10.1
25 optic nerve disease 10.1
26 retinal degeneration 10.1
27 scotoma 10.1
28 nonarteritic anterior ischemic optic neuropathy 10.0
29 kuhnt-junius degeneration 10.0
30 vitreous syneresis 10.0
31 neovascular glaucoma 10.0
32 vascular disease 10.0
33 neuropathy 10.0
34 47,xyy 10.0
35 optic disc pit 10.0
36 vitreoretinopathy 10.0
37 diabetes mellitus, noninsulin-dependent 9.9
38 fibrosis of extraocular muscles, congenital, 1 9.9
39 glaucoma, primary open angle 9.9
40 systemic lupus erythematosus 9.9
41 retinoblastoma 9.9
42 vitreoretinopathy, neovascular inflammatory 9.9
43 retinoschisis 1, x-linked, juvenile 9.9
44 astigmatism 9.9
45 pars planitis 9.9
46 cytomegalovirus retinitis 9.9
47 isolated ectopia lentis 9.9
48 disseminated intravascular coagulation 9.9
49 retinal vasculitis 9.9
50 retinal lattice degeneration 9.9

Graphical network of the top 20 diseases related to Vitreous Detachment:



Diseases related to Vitreous Detachment

Symptoms & Phenotypes for Vitreous Detachment

UMLS symptoms related to Vitreous Detachment:


eye manifestations

MGI Mouse Phenotypes related to Vitreous Detachment:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.73 FN1 KCNMA1 LAMA5 OPTC PLG VEGFA
2 growth/size/body region MP:0005378 9.63 FN1 KCNMA1 LAMA5 PLG SLC44A2 VEGFA
3 hearing/vestibular/ear MP:0005377 9.26 KCNMA1 LAMA5 LHFPL5 SLC44A2
4 nervous system MP:0003631 9.17 FN1 KCNMA1 LAMA5 LHFPL5 PLG SLC44A2

Drugs & Therapeutics for Vitreous Detachment

Drugs for Vitreous Detachment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Temazepam Approved, Investigational Phase 4 846-50-4 5391
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5 Angiogenesis Inhibitors Phase 4
6 Angiogenesis Modulating Agents Phase 4
7 Antineoplastic Agents, Immunological Phase 4
8 Neurotransmitter Agents Phase 4
9 Tranquilizing Agents Phase 4
10 Anti-Anxiety Agents Phase 4
11 GABA Agents Phase 4
12 Hypnotics and Sedatives Phase 4
13 GABA Modulators Phase 4
14 Central Nervous System Depressants Phase 4
15 Psychotropic Drugs Phase 4
16 Hormone Antagonists Phase 4
17 Antiemetics Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Gastrointestinal Agents Phase 4
20 HIV Protease Inhibitors Phase 4
21 glucocorticoids Phase 4
22 Hormones Phase 4
23 Peripheral Nervous System Agents Phase 4
24 Antineoplastic Agents, Hormonal Phase 4
25
protease inhibitors Phase 4
26 BB 1101 Phase 4
27 Autonomic Agents Phase 4
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
29
Ranibizumab Approved Phase 2 347396-82-1 459903
30
Fibrinolysin Investigational Phase 2 9004-09-5
31 Pharmaceutical Solutions Phase 2
32 Fibrinolytic Agents Phase 2
33 Plasminogen Phase 1, Phase 2
34
Triamcinolone Approved, Vet_approved 124-94-7 31307
35
Dipivefrin Approved 52365-63-6 3105
36
tannic acid Approved 1401-55-4
37
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
38 Tetrahydrozoline
39 Proxymetacaine
40 triamcinolone acetonide
41 Triamcinolone diacetate
42 Triamcinolone hexacetonide
43 Tissue Plasminogen Activator

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Combined Therapy in ARMD - Retrospective Case Series Completed NCT00805649 Phase 4 dexamethasone;bevacizumab;triamcincolone
2 A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients. Unknown status NCT00908778 Phase 3 Vitreosolve;Vitreosolve
3 Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin Unknown status NCT00996684 Phase 2 Microplasmin;Placebo control
4 An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy Completed NCT00198471 Phase 2 Vitrase
5 A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of DME. Completed NCT00412451 Phase 2 ocriplasmin
6 A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of Vitreomacular Traction (VMT). Completed NCT00435539 Phase 2 ocriplasmin;ocriplasmin;Sham Comparator
7 An Open Label, Single Centre Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion Completed NCT01055535 Phase 2 Microplasmin
8 Posterior Vitreous Detachment (PVD) Assessment During Dual RVO Lucentis Evaluations (PADDLE Study) Completed NCT00831350 Phase 2 Ranibizumab
9 A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial Completed NCT00412958 Phase 2 Ocriplasmin 25µg;Ocriplasmin 75µg;Ocriplasmin 125µg;Placebo
10 Protocol PVD-202: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD in Non-Proliferative Diabetic Retinopathy Completed NCT02435862 Phase 2 1.0mg Luminate®;2.0mg Luminate®;3.0mg Luminate®
11 A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
12 A Multicenter, Randomized, Double Masked, Placebo Controlled, Sequential Dose Response Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) Terminated NCT00348439 Phase 2 Plasmin;Vehicle
13 An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD) Terminated NCT00347646 Phase 1, Phase 2 Plasmin
14 Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema Terminated NCT01194674 Phase 1, Phase 2 Microplasmin
15 Partial Posterior Hyaloidectomy in Macular Surgery : A Modified Procedure of Vitrectomy to Prevent Retinal Break Related to Induction of a Posterior Vitreous Detachment Completed NCT01454466 Phase 1
16 A Phase 1, Randomized, Sham-Controlled, Double-Masked, Dose Escalation, Multi-Center Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment Not yet recruiting NCT03780972 Phase 1 ONL1204
17 Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients Unknown status NCT02290795
18 Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation Unknown status NCT00673296 Intravitreal Bevacizumab
19 Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy Completed NCT01256632 Ranibizumab
20 A Prospective Randomized Controlled Trial Evaluating the Safety and Efficacy of YAG Vitreolysis Versus Sham for Symptomatic Weiss Ring Due to Posterior Vitreous Detachment Completed NCT02897583
21 Ultrastructure Analysis of Excised Internal Limiting Membrane in Eyes of Highly Myopia With Myopic Traction Maculopathy Completed NCT02528058
22 Randomized Trial of Laser Ablation for Highly Symptomatic Floaters Completed NCT01970267
23 Assessment of Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal Completed NCT01474655
24 Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography Completed NCT01220804
25 OCT Documents Vitreo-papillary Traction Completed NCT03460600
26 Vitrectomy Without Laser or Gas Tamponade for Optic Disc Pit Maculopathy Completed NCT01340703
27 High-frequency-ultrasound Annular Arrays for Small Animal and Ophthalmic Imaging Completed NCT00633854
28 Intravitreal Administration of Ranibizumab Combined With Intravitreous Injection of Expansile Gas and Induction of Posterior Vitreous Detachment in Treatment of Exudative AMD With Posterior VMA: a Pilot, Open Label, Comparative Study Completed NCT01291121
29 Phase 1 Study of Optical Coherence Tomography Images to Identify the Prevalence of Vitreomacular Adhesion and Associated Maculopathies Completed NCT02160340
30 Vitrectomy for Persistent Macular Edema in Branch Retinal Vein Occlusion Completed NCT00685490
31 High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging Completed NCT01415037
32 Extent of Internal Limiting Membrane Removal and Its Impact on Outcomes of Macular Hole Surgery Completed NCT02010138
33 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
34 Role of Intraoperative Dexamethasone Implant in Improving Outcome of Taut Posterior Hyaloid Removal in Diabetic Macular Edema Completed NCT01698788 Dexamethasone Drug delivery system (Ozurdex)
35 Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies Completed NCT00408720
36 Influence of Posterior Vitreous Detachment on Retinal Detachment After Lens Surgery in Myopic Eyes Recruiting NCT03152747
37 YAG Laser Vitreolysis of Symptomatic Vitreal Floaters Recruiting NCT03970148
38 Comparing the Surgical Outcomes of Internal Limiting Membrane Peeling-reposition Versus Peeling in Idiopathic Macular Holes: A Randomized Controlled Trial Active, not recruiting NCT03020459 Brilliant Blue G
39 Vitreomacular Interface Abnormalities Indiabetic Retinopathy Using Ocular Coherence Tomography Not yet recruiting NCT03686436
40 Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient Terminated NCT02783209
41 Evaluation of the Role of Intravitreal Injection of TPA in Treatment of Refractory Diabetic Macular Edema Terminated NCT01141881 Tissue Plasminogen Activator,bevacizumab ,follow up
42 Intravitreal Injection of Expansile Sulfa Hexafluoride Gas for Symptomatic Vitreomacular Adhesion Withdrawn NCT02001701

Search NIH Clinical Center for Vitreous Detachment

Cochrane evidence based reviews: vitreous detachment

Genetic Tests for Vitreous Detachment

Anatomical Context for Vitreous Detachment

MalaCards organs/tissues related to Vitreous Detachment:

41
Eye, Retina, Cortex, Endothelial, Brain, Testes

Publications for Vitreous Detachment

Articles related to Vitreous Detachment:

(show top 50) (show all 1253)
# Title Authors PMID Year
1
Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. 9 38
18040240 2007
2
The effect of tissue plasminogen activator on premacular hemorrhage. 9 38
11195747 2001
3
OBSERVATION OF VITREOUS FEATURES USING ENHANCED VITREOUS IMAGING OPTICAL COHERENCE TOMOGRAPHY IN HIGHLY MYOPIC RETINOSCHISIS. 38
29912094 2019
4
Perfluoro-n-octane-assisted mega Weiss-ring technique for posterior vitreous detachment induction in retinal detachment. 38
31436194 2019
5
Point-of-care ultrasound for the evaluation of non-traumatic visual disturbances in the emergency department: The VIGMO protocol. 38
31130372 2019
6
Cost-Effectiveness of Limited Vitrectomy for Vision-Degrading Myodesopsia. 38
30849342 2019
7
Posterior vitreous detachment and incidence of delayed retinal breaks: a retrospective, 2-year study at an academic centre. 38
31358152 2019
8
Characterization of Epiretinal Proliferation in Full-Thickness Macular Holes and Effects on Surgical Outcomes. 38
31104985 2019
9
[Vitreomacular Interface Diseases: Vitreomacular Adhesion, Vitreomacular Traction, Epiretinal Membranes, and Macular Hole]. 38
31416094 2019
10
Observation of anterior chamber volume after cataract surgery with swept-source optical coherence tomography. 38
30182270 2019
11
CHANGES IN THE POSTERIOR VITREOUS AFTER CATARACT SURGERY ASSESSED BY SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY. 38
28277441 2019
12
Evaluation of posterior vitreous detachment using ultrasonography and optical coherence tomography. 38
31301107 2019
13
ALTERATIONS OF MACULAR BLOOD FLOW IN SUPERFICIAL AND DEEP CAPILLARY PLEXUSES IN THE FELLOW AND AFFECTED EYES OF PATIENTS WITH UNILATERAL IDIOPATHIC EPIRETINAL MEMBRANE. 38
31305504 2019
14
Effect of vitreomacular adhesion on the treatment outcomes in the STOP-Uveitis clinical trial for non-infectious uveitis. 38
31325001 2019
15
Intrachoroidal cavitation in myopic eyes. 38
31300972 2019
16
Ultrasonographic characteristics of active ocular toxoplasmosis. 38
31038555 2019
17
Examiner Position in Ocular Point-of-Care Ultrasound: A Proposed Technique. 38
31003818 2019
18
Symptoms related to posterior vitreous detachment and the risk of developing retinal tears: a systematic review. 38
30632695 2019
19
Using the Retrobulbar Spot Sign to Assist in Diagnosis and Management of Central Retinal Artery Occlusions. 38
31228289 2019
20
Posterior Vitreous Detachment and the Associated Risk of Retinal Toxicity with Intravitreal Melphalan Treatment for Retinoblastoma. 38
31367584 2019
21
POSTERIOR FUNDUS HEMORRHAGES: Frequency and Associated Factors: The Beijing Eye Study. 38
29533284 2019
22
Vitreous Biopsy Under Air: Technique, Complications, and Volume Outcomes. 38
31233153 2019
23
Outcome and Predictors for 2-Year Visual Acuity in Eyes with Diabetic Macular Edema Treated with Ranibizumab. 38
30896316 2019
24
Iatrogenic retinal breaks and postoperative retinal detachments in microincision vitrectomy surgery compared with conventional 20-gauge vitrectomy: a meta-analysis. 38
30560911 2019
25
STRICT POSTURING WITH OR WITHOUT BILATERAL PATCHING FOR POSTERIOR VITREOUS DETACHMENT-RELATED VITREOUS HEMORRHAGE. 38
31136460 2019
26
Ophthalmological emergencies. An epidemiological study: Are resources been used properly? 38
30837174 2019
27
Point-of-Care Ultrasonography in the Diagnosis of Retinal Detachment, Vitreous Hemorrhage, and Vitreous Detachment in the Emergency Department. 38
30977855 2019
28
Long-term outcomes of patients with myopic traction maculopathy after phacoemulsification for incident cataract. 38
30952957 2019
29
RESOLUTION OF FOVEAL CYST AFTER THE RELEASE OF VITREOMACULAR ATTACHMENT IN EYE WITH MACULAR TELANGIECTASIA TYPE 2. 38
28248745 2019
30
Vitreomacular Traction and Outer Retinal Structural Changes 38
31055898 2019
31
Sex-Related Differences in the Progression of Posterior Vitreous Detachment with Age. 38
31014700 2019
32
MULTILAYERED OPTIC DISK HEMORRHAGE IN ADULTS WITHOUT A POSTERIOR VITREOUS DETACHMENT. 38
30932996 2019
33
Indocyanine Green-Assisted Internal Limiting Membrane Peeling to Induce Posterior Vitreous Detachment in the Cases With Strong Vitreoretinal Adhesion. 38
30893274 2019
34
Lack of Major Ophthalmic Findings in Patients with Primary Familial Brain Calcification Linked to SLC20A2 and PDGFB. 38
30607898 2019
35
[UNUSUAL VITREOUS DETACHMENT]. 38
30779488 2019
36
Early posterior vitreous detachment is associated with LAMA5 dominant mutation. 38
30589377 2019
37
Efficacy of non-fovea-sparing ILM peeling for symptomatic myopic foveoschisis with and without macular hole. 38
29712637 2019
38
Pathogenesis and Management of Macular Hole: Review of Current Advances. 38
31191994 2019
39
LONGITUDINAL CHANGES IN THE OPTIC NERVE HEAD AND RETINA OVER TIME IN VERY YOUNG CHILDREN WITH FAMILIAL EXUDATIVE VITREORETINOPATHY. 38
29190238 2019
40
Absence of Posterior Vitreous Detachment Is a Risk Factor of Severe Bleb-Related Endophthalmitis. 38
30755799 2019
41
Predominantly Superior Retinal Tears Detected by B-Scan Ultrasonography. 38
31308974 2019
42
RETINAL DETACHMENT ASSOCIATED WITH PERIPAPILLARY STAPHYLOMA IMAGED WITH SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY. 38
28072615 2019
43
LINCOFF RULES ARE NOT FOLLOWED IN RETINAL DETACHMENT WITH POSTERIOR BREAKS AND ATTACHED CORTICAL VITREOUS. 38
30562236 2019
44
International multi-center study of iatrogenic retinal tears in pars plana vitrectomy. 38
31236359 2019
45
Fibrin Glue and Internal Limiting Membrane Abrasion for Optic Disc Pit Maculopathy. 38
30566713 2018
46
Pars plana vitrectomy in management of giant retinal tear and retinal detachment following iris-fixated anterior chamber phakic intraocular lens implantation. 38
30580313 2018
47
The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration. 38
30451182 2018
48
Spectral-Domain Optical Coherence Tomography of the Vitreopapillary Interface in Acute Nonarteritic Anterior Ischemic Optic Neuropathy. 38
30098345 2018
49
Full-thickness macular hole associated with congenital simple hamartoma of retinal pigment epithelium (CSHRPE). 38
28828540 2018
50
ULTRASONOGRAPHIC FINDINGS IN THE VITREOUS OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. 38
28820850 2018

Variations for Vitreous Detachment

Expression for Vitreous Detachment

Search GEO for disease gene expression data for Vitreous Detachment.

Pathways for Vitreous Detachment

GO Terms for Vitreous Detachment

Cellular components related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA PLG OPTC LAMA5 FN1
2 collagen-containing extracellular matrix GO:0062023 9.33 PLG LAMA5 FN1
3 basement membrane GO:0005604 9.32 LAMA5 FN1
4 extracellular matrix GO:0031012 9.26 VEGFA OPTC LAMA5 FN1
5 platelet alpha granule lumen GO:0031093 8.8 VEGFA PLG FN1

Biological processes related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.54 VEGFA LAMA5 FN1
2 angiogenesis GO:0001525 9.43 VEGFA LAMA5 FN1
3 substrate adhesion-dependent cell spreading GO:0034446 9.32 LAMA5 FN1
4 branching morphogenesis of an epithelial tube GO:0048754 9.16 VEGFA LAMA5
5 platelet degranulation GO:0002576 9.13 VEGFA PLG FN1
6 interaction with symbiont GO:0051702 8.62 PLG FN1

Molecular functions related to Vitreous Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.13 PLG LAMA5 FN1
2 extracellular matrix structural constituent GO:0005201 8.8 OPTC LAMA5 FN1

Sources for Vitreous Detachment

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....